Monday, November 4, 2013
Xencor Sets IPO Pricing Range
Monrovia, California-based Xencor, the biopharmaceuticals technology developer headed by Bassil Dahiyat, has set its IPO pricing range, saying today in a regulatory filing that it is expecting to price its IPO at between $14.00 and $16.00 per share. The company is looking to trade as XNCR on the NASDAQ Global Market. Xencor had filed for an IPO in October. Xencor is backed by MedImmune Ventures, HealthCare Ventures, and John R. Stafford, III.